tetano
Editor, Senior Moderator
Acta Anaesthesiol Scand
. 2021 Dec 24.
doi: 10.1111/aas.14023. Online ahead of print.
Higher vs lower oxygenation targets in COVID-19 patients with severe hypoxaemia (HOT-COVID) trial: protocol for a secondary Bayesian analysis
Frederik Mølgaard Nielsen[SUP] 1 2 3 [/SUP], Thomas Lass Klitgaard[SUP] 1 2 3 [/SUP], Anders Granholm[SUP] 3 4 [/SUP], Theis Lange[SUP] 3 5 [/SUP], Anders Perner[SUP] 3 4 [/SUP], Olav Lilleholt Schjørring[SUP] 1 2 3 [/SUP], Bodil Steen Rasmussen[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Background: Respiratory failure is the main cause of mortality and morbidity among ICU patients with coronavirus disease 2019 (COVID-19). In these patients, supplemental oxygen therapy is essential, but there is limited evidence the optimal target. To address this, the ongoing handling oxygenation targets in COVID-19 (HOT-COVID) trial was initiated to investigate the effect of a lower oxygenation target (partial pressure of arterial oxygen (PaO[SUB]2[/SUB] ) of 8 kPa) vs a higher oxygenation target (PaO[SUB]2[/SUB] of 12 kPa) in the ICU on clinical outcome in patients with COVID-19 and hypoxaemia.
Methods: The HOT-COVID is planned to enrol 780 patients. This paper presents the protocol and statistical analysis plan for the conduct of a secondary Bayesian analysis of the primary outcome of HOT-COVID being days alive without life-support at 90 days and the secondary outcome 90-day all-cause mortality. Further, both outcomes will be investigated for the presence heterogeneity of treatment effects based on four baseline parameters being sequential organ failure assessment score, PaO[SUB]2[/SUB] /fraction of inspired oxygen ratio, highest dose of norepinephrine during the 24 hours before randomisation, and plasma concentration of lactate at randomisation.
Conclusion: The results of this pre-planned secondary Bayesian analysis will complement the primary frequentist analysis of the HOT-COVID trial and may facilitate a more nuanced interpretation of the trial results.
. 2021 Dec 24.
doi: 10.1111/aas.14023. Online ahead of print.
Higher vs lower oxygenation targets in COVID-19 patients with severe hypoxaemia (HOT-COVID) trial: protocol for a secondary Bayesian analysis
Frederik Mølgaard Nielsen[SUP] 1 2 3 [/SUP], Thomas Lass Klitgaard[SUP] 1 2 3 [/SUP], Anders Granholm[SUP] 3 4 [/SUP], Theis Lange[SUP] 3 5 [/SUP], Anders Perner[SUP] 3 4 [/SUP], Olav Lilleholt Schjørring[SUP] 1 2 3 [/SUP], Bodil Steen Rasmussen[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 34951717
- DOI: 10.1111/aas.14023
Abstract
Background: Respiratory failure is the main cause of mortality and morbidity among ICU patients with coronavirus disease 2019 (COVID-19). In these patients, supplemental oxygen therapy is essential, but there is limited evidence the optimal target. To address this, the ongoing handling oxygenation targets in COVID-19 (HOT-COVID) trial was initiated to investigate the effect of a lower oxygenation target (partial pressure of arterial oxygen (PaO[SUB]2[/SUB] ) of 8 kPa) vs a higher oxygenation target (PaO[SUB]2[/SUB] of 12 kPa) in the ICU on clinical outcome in patients with COVID-19 and hypoxaemia.
Methods: The HOT-COVID is planned to enrol 780 patients. This paper presents the protocol and statistical analysis plan for the conduct of a secondary Bayesian analysis of the primary outcome of HOT-COVID being days alive without life-support at 90 days and the secondary outcome 90-day all-cause mortality. Further, both outcomes will be investigated for the presence heterogeneity of treatment effects based on four baseline parameters being sequential organ failure assessment score, PaO[SUB]2[/SUB] /fraction of inspired oxygen ratio, highest dose of norepinephrine during the 24 hours before randomisation, and plasma concentration of lactate at randomisation.
Conclusion: The results of this pre-planned secondary Bayesian analysis will complement the primary frequentist analysis of the HOT-COVID trial and may facilitate a more nuanced interpretation of the trial results.